{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:30:02Z","timestamp":1756312202775,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010905","name":"Major Research Plan","doi-asserted-by":"publisher","award":["81470369"],"award-info":[{"award-number":["81470369"]}],"id":[{"id":"10.13039\/501100010905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13148-018-0597-6","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T09:10:22Z","timestamp":1545297022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses"],"prefix":"10.1186","volume":"10","author":[{"given":"Qiumei","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chor Sang","family":"Chim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,20]]},"reference":[{"key":"597_CR1","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","volume":"28","author":"BA Walker","year":"2013","unstructured":"Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2013;28:384\u201390.","journal-title":"Leukemia"},{"key":"597_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91\u2013101.","journal-title":"Cancer Cell"},{"key":"597_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8:268.","journal-title":"Nat Commun"},{"key":"597_CR4","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/sj.leu.2404205","volume":"20","author":"CS Chim","year":"2006","unstructured":"Chim CS, Liang R, Leung MH, Yip SF, Kwong YL. Aberrant gene promoter methylation marking disease progression in multiple myeloma. Leukemia. 2006;20:1190\u20132.","journal-title":"Leukemia"},{"key":"597_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2013-03-487884","volume":"122","author":"MF Kaiser","year":"2013","unstructured":"Kaiser MF, Johnson DC, Wu P, Walker BA, Brioli A, Mirabella F, et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood. 2013;122:219\u201326.","journal-title":"Blood"},{"key":"597_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","volume":"117","author":"BA Walker","year":"2011","unstructured":"Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. 2011;117:553\u201362.","journal-title":"Blood"},{"key":"597_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-016-0336-4","volume":"9","author":"Y Bai","year":"2016","unstructured":"Bai Y, Wong KY, Fung TK, Chim CS. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers\/probes. J Hematol Oncol. 2016;9:107.","journal-title":"J Hematol Oncol"},{"key":"597_CR8","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1182\/blood-2003-06-2007","volume":"103","author":"CS Chim","year":"2004","unstructured":"Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak\/STAT pathway. Blood. 2004;103:4630\u20135.","journal-title":"Blood"},{"key":"597_CR9","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1038\/leu.2015.7","volume":"29","author":"N Puig","year":"2015","unstructured":"Puig N, Conde I, Jimenez C, Sarasquete ME, Balanzategui A, Alcoceba M, et al. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. Leukemia. 2015;29:1435\u20137.","journal-title":"Leukemia"},{"key":"597_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/ng.3683","volume":"48","author":"JJ Hao","year":"2016","unstructured":"Hao JJ, Lin DC, Dinh HQ, Mayakonda A, Jiang YY, Chang C, et al. Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. Nat Genet. 2016;48:1500\u20137.","journal-title":"Nat Genet"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-018-0597-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-018-0597-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-018-0597-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T19:03:01Z","timestamp":1576782181000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-018-0597-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["597"],"URL":"https:\/\/doi.org\/10.1186\/s13148-018-0597-6","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"type":"print","value":"1868-7075"},{"type":"electronic","value":"1868-7083"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"11 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board of the University of Hong Kong\/Hospital Authority Hong Kong West Cluster (HKU\/HA HKW IRB, IRB Reference Number: UW 05\u2013269\u2009T\/932) with informed consents.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"158"}}